FDA Advisors Support New Alzheimer's Drug, Donanemab

TUESDAY, June 11, 2024 -- A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer's outweigh its harms, which can include brain swelling and bleeding.

Eli Lilly's...